Journal Home
Search for

Volume 144, Issue 1, Pages 187-199 (July 2009)


View previous. 33 of 36 View next.

Differential regulation of TRP channels in a rat model of neuropathic pain

Susanne Staafab, Sandra Oertherc, Guilherme Lucasd, Jan P. Mattssone, Patrik ErnforsbCorresponding Author Informationemail address

Received 12 December 2008; received in revised form 14 April 2009; accepted 15 April 2009. published online 18 May 2009.

Abstract 

Neuropathic pain is a chronic disease resulting from dysfunction of the nervous system often due to peripheral nerve injury. Hypersensitivity to sensory stimuli (mechanical, thermal or chemical) is a common source of pain in patients and ion channels involved in detecting these stimuli are possible candidates for inducing and/or maintaining the pain. Transient receptor potential (TRP) channels expressed on nociceptors respond to different sensory stimuli and a few of them have been studied previously in the models of neuropathic pain. Using real-time PCR for quantification of all known TRP channels we identified several TRP channels, which have not been associated with nociception or neuropathic pain before, to be expressed in the DRG and to be differentially regulated after spared nerve injury (SNI). Of all TRP channel members, TRPML3 showed the most dramatic change in animals exhibiting neuropathic pain behaviour compared to control animals. In situ hybridisation showed a widespread increase of expression in neurons of small, medium and large cell sizes, indicating expression in multiple subtypes. Co-localisation of TRPML3 with CGRP, NF200 and IB4 staining confirmed a broad subtype distribution. Expression studies during development showed that TRPML3 is an embryonic channel that is induced upon nerve injury in three different nerve injury models investigated. Thus, the current results link for the first time a re-expression of TRPML3 with the development of neuropathic pain conditions. In addition, decreased mRNA levels after SNI were seen for TRPM6, TRPM8, TRPV1, TRPA1, TRPC3, TRPC4 and TRPC5.

a Department of Bioscience, AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden

b Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden

c Department of Disease Biology, AstraZeneca R&D Södertälje, 151 85 Södertälje, Sweden

d Department of Physiology, Ribeirão Preto School of Medicine, University of São Paulo, 14049-900 Ribeirão Preto - SP, Brazil

e Albireo AB, 430 33 Göteborg, Sweden

Corresponding Author InformationCorresponding author. Address: Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheelsv. 1, 171 77 Stockholm, Sweden. Tel.: +46 8 52487659.

PII: S0304-3959(09)00221-8

doi:10.1016/j.pain.2009.04.013


View previous. 33 of 36 View next.